Lockheed's record backlog proves demand, not profit yet

Is a $292 billion backlog a forecast of the future or just a very large number? For Lockheed Martin, it's both, and investors who confuse the two are the ones most likely to get hurt.

On October 22, Lockheed reported third-quarter sales of $20.7 billion, up 11%, and net earnings of $1.845 billion, or $7.97 per diluted share. Backlog hit a record $292.0 billion, up 27% since the second quarter, including $52.5 billion tied to a multi-year PAC-3 interceptor award. The company raised its 2026 outlook for the second straight quarter, according to StockTitan's summary of the release: sales of roughly $80–$82 billion, EPS of $30.35–$30.75 and free cash flow of $7.8–$8.0 billion.

The backlog is the strongest evidence yet that rearmament is not a blip

Last quarter the backlog was $230 billion. It has since jumped by about $62 billion, and $52.5 billion of that is the PAC-3 award alone. The previous record was built on another giant multi-year munitions deal, the $35 billion THAAD contract with the Missile Defense Agency. Contracts like these are not impulse purchases. Governments sign multi-year deals when they expect to keep buying.

That's why we think the "structural demand" thesis is mostly right. The customers are governments, and, as TradingKey put it in July, they rarely cancel existing contracts. Backlog at about 3.6 times annual sales, going by the $80–$82 billion outlook, is unusual visibility for almost any industry. If you believe defense budgets stay elevated, this is what that belief looks like on a balance sheet.

But "structural" is a claim about demand, not about shareholder returns. Those are different things.

A backlog is a promise to work, not a promise to get paid on time

Here is the detail the headline glosses over. In the same quarter that sales rose 11% and earnings rose 14%, operating cash flow fell to $3.438 billion from $3.728 billion, and free cash flow slipped to $2.999 billion from $3.347 billion. The raised full-year cash guidance is still encouraging, but the quarter itself went the other way.

Context matters too. Last quarter's cash comparison looked spectacular, $2.9 billion against negative $150 million a year earlier, but Lockheed attributed the swing primarily to the timing of customer receipts and lower tax payments, and the year-ago quarter was weighed down by $1.6 billion in program losses. Easy comparisons flatter growth rates. We'd treat part of the year-over-year improvement as a base effect.

Then there's the F-35. The company warned that Lot 20 costs began exceeding authorized funding, with negative financial effects possible if additional authorization and funding don't arrive. In our view, a backlog this large also means a lot of execution risk: munitions production has to ramp, and new partnerships such as those with GM Defense and Rheinmetall have to deliver. The 2025 reach-forward losses are a reminder that a signed contract can still lose money.

The market has already paid for good news, so the price is the question

On the day of the report, the shares were up 3.60% at $571.35 in delayed trading, on heavy volume. In July, TradingKey noted the stock had jumped more than 5% after earnings and was technically overbought. It looks to us like the stock keeps being rewarded for exactly this story.

We won't tell you whether $571 is cheap or expensive; we don't have a reliable valuation multiple to offer, and guessing would be unfair to you. What we can offer is the framework. Take the guidance midpoint of $30.55 in EPS, compute the multiple yourself and compare it with your own view of how long growth lasts.

Our verdict: believe the demand, audit the conversion

The backlog is the best argument that defense spending is a multi-year cycle, not a headline-driven spike. Nothing in this report undermines that. But for an investor, three things deserve more attention than the record number: whether free cash flow keeps tracking the raised $7.8–$8.0 billion target, whether the F-35 funding gap gets resolved, and whether the share price leaves any margin for disappointment.

In our view, if you already own Lockheed through a diversified fund, this report is a reason for calm rather than action. If you're considering buying after a run, remember that great visibility on revenue may already be in the price. This is analysis, not personalized advice, and past strength doesn't promise future returns. Rearmament may well be permanent. Your entry price isn't.